NodThera
Generated by Meeveem AI
"Developing oral therapies that target inflammation at its source to treat chronic disease"
Boston, MA
•11 - 50 Employees
•Biotechnology
About NodThera
NodThera develops a new class of oral medicines that target the NLRP3 inflammasome, a key driver of chronic inflammation underlying diseases of the body and brain. Their small molecule inhibitors cross cell membranes and the blood brain barrier, offering a more accessible treatment approach than existing biologics for cardiovascular disease, obesity, and neuroinflammation. The company's pipeline includes brain penetrant candidates in clinical trials, addressing millions of patients with limited treatment options. By inhibiting inflammation at its upstream source rather than downstream symptoms, NodThera aims to transform outcomes for chronic inflammatory conditions affecting quality of life and long term health.
24
Team Members
2016
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where chronic diseases driven by inflammation are curable at their biological source, not merely managed through symptom relief, giving millions back their health and quality of life.
Our Mission
At NodThera, our mission is to deliver viable, targeted medicines for chronic inflammatory diseases by unlocking the potential of NLRP3 inflammasome inhibition.